Home
|
About us
|
Contact us
About AWMSG
All Wales Medicines Strategy Group (AWMSG)
New Medicines Group (NMG)
All Wales Prescribing Advisory Group (AWPAG)
Meetings
Appraisals
Appraisal information
Patients/carers/patient organisations
Healthcare professionals
Pharmaceutical industry
Search and reports
Search and browse
Reports
Medicines management
About
Forthcoming work programme
National prescribing indicators
Clinical effectiveness prescribing programme
Appraisal monitoring
In-patient medication administration record
Patient information leaflets
Library
denosumab (Xgeva®)
Reference No. 1870
Publication date:
10/12/2015
Appraisal information
denosumab (Xgeva®) 120 mg solution for injection
Company:
Amgen Ltd
BNF category:
Endocrine system
NMG meeting date:
07/10/2015
AWMSG meeting date:
11/11/2015
Submission Type:
Limited Submission
Status:
Recommended
Advice No:
3815
Ratification by Welsh Government:
09/12/2015
Current Progress
Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government
AWMSG advice
Denosumab (Xgeva®) is recommended for use within NHS Wales for the treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity. This recommendation applies only in circumstances where the approved Patient Access Scheme is utilised.
Final Appraisal Recommendation (FAR)
Download
denosumab (Xgeva) 1870 FAR
AWMSG Secretariat Appraisal Report (ASAR)
Download
denosumab (Xgeva) 1870 ASAR
Clinical Expert (CE) Summary
Download
denosumab (Xgeva) 1870 CE summary